Literature DB >> 15271856

Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma.

Tong Sun1, Xiaoping Miao, Jinwei Wang, Wen Tan, Yifeng Zhou, Chunyuan Yu, Dongxin Lin.   

Abstract

Aurora-A/BTAK/STK15, involved in regulating centrosomes and chromosome segregation, is overexpressed in human breast carcinoma and other cancers. The Phe31-->Ile polymorphism in Aurora A alters the kinase function, with the Ile31 variant being preferentially amplified and associated with degree of aneuploidy in human tumors. We have previously shown that the Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal cancer. This case-control study examined the contribution of this polymorphism to susceptibility to development and progression of breast cancer. Aurora A genotypes were determined in 520 patients with breast carcinoma, 191 patients with benign breast diseases (BBD) and 520 controls. It was found that the Aurora A Ile/Ile genotype was significantly associated with increased risk of breast carcinoma occurrence [odds ratio (OR) 1.66; 95% confidence interval (95% CI) 1.29-2.12] compared with the Phe/Phe or Phe/Ile genotype. The increased risk for BBD and breast carcinoma related to the Ile/Ile genotype was more pronounced in younger subjects. Moreover, we found that patients carrying the Ile/Ile genotype tended to have ER-carcinomas (OR 2.56; 95% CI 1.24-5.26). No significant association was observed between the polymorphism and metastasis and disease stage of the cancer. These findings suggest that the Phe31Ile polymorphism in Aurora A may be a genetic modifier for developing breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271856     DOI: 10.1093/carcin/bgh244

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

1.  Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal:  Mol Genet Genomics       Date:  2014-08-26       Impact factor: 3.291

2.  AURKA Phe31Ile polymorphism interacted with use of alcohol, betel quid, and cigarettes at multiplicative risk of oral cancer occurrence.

Authors:  Chi-Pin Lee; Shang-Lun Chiang; Chien-Hung Lee; Yi-Shan Tsai; Zhi-Hong Wang; Chun-Hung Hua; Yuan-Chien Chen; Eing-Mei Tsai; Ying-Chin Ko
Journal:  Clin Oral Investig       Date:  2015-02-21       Impact factor: 3.573

3.  Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.

Authors:  Nicholas J Taylor; Jeannette T Bensen; Charles Poole; Melissa A Troester; Marilie D Gammon; Jingchun Luo; Robert C Millikan; Andrew F Olshan
Journal:  Mol Carcinog       Date:  2014-10-18       Impact factor: 4.784

4.  Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population.

Authors:  Andrés López-Cortés; Alejandro Cabrera-Andrade; Fabián Oña-Cisneros; Carolina Echeverría; Felipe Rosales; Malena Ortiz; Eduardo Tejera; César Paz-Y-Miño
Journal:  Pathol Oncol Res       Date:  2017-06-24       Impact factor: 3.201

5.  The GTEx Consortium atlas of genetic regulatory effects across human tissues.

Authors: 
Journal:  Science       Date:  2020-09-11       Impact factor: 47.728

6.  Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Authors:  Noa Matarasso; Anat Bar-Shira; Uri Rozovski; Serena Rosner; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

7.  The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.

Authors:  Neal Jetton; Karen G Rothberg; James G Hubbard; John Wise; Yan Li; Haydn L Ball; Larry Ruben
Journal:  Mol Microbiol       Date:  2009-03-06       Impact factor: 3.501

8.  AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.

Authors:  Fergus J Couch; Olga Sinilnikova; Robert A Vierkant; V Shane Pankratz; Zachary S Fredericksen; Dominique Stoppa-Lyonnet; Isabelle Coupier; David Hughes; Agnès Hardouin; Pascaline Berthet; Susan Peock; Margaret Cook; Caroline Baynes; Shirley Hodgson; Patrick J Morrison; Mary E Porteous; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Amanda B Spurdle; Rita Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Christian Sutter; Jurgen Horst; Dieter Schaefer; Kenneth Offit; Tomas Kirchhoff; Irene L Andrulis; Eduard Ilyushik; Gordon Glendon; Peter Devilee; Maaike P G Vreeswijk; Hans F A Vasen; Ake Borg; Katja Backenhorn; Jeffery P Struewing; Mark H Greene; Susan L Neuhausen; Timothy R Rebbeck; Katherine Nathanson; Susan Domchek; Theresa Wagner; Judy E Garber; Csilla Szabo; Michal Zikan; Lenka Foretova; Janet E Olson; Thomas A Sellers; Noralane Lindor; Heli Nevanlinna; Johanna Tommiska; Kristiina Aittomaki; Ute Hamann; Muhammad U Rashid; Diana Torres; Jacques Simard; Francine Durocher; Frederic Guenard; Henry T Lynch; Claudine Isaacs; Jeffrey Weitzel; Olufunmilayo I Olopade; Steven Narod; Mary B Daly; Andrew K Godwin; Gail Tomlinson; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-07       Impact factor: 4.254

9.  Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.

Authors:  Núria Bonifaci; Antoni Berenguer; Javier Díez; Oscar Reina; Ignacio Medina; Joaquín Dopazo; Víctor Moreno; Miguel Angel Pujana
Journal:  BMC Med Genomics       Date:  2008-12-18       Impact factor: 3.063

10.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.